At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 9 enrolled
Drug / intervention
AST-VAC2biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 1 clinical trial evaluating AST-VAC2 for Advanced Non-small Cell Lung Cancer. Completed, enrolled 9 participants across 2 sites.
Detailed Summary
This clinical study is looking at a vaccine called AST-VAC2 in adult patients with advanced non-small cell lung cancer (NSCLC). The main aim of the study: If the dose can be given safely to patients, learn more about the potential side effects of the vaccine and how they can be managed and also what happens to AST-VAC2 inside the body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Non-small Cell Lung Cancer
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartMay 2018
Primary CompletionAug 2022
TodayJul 2026
First PostedDec 13, 2017
Enrollment StartMay 29, 2018
Primary CompletionAug 8, 2022
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 8.6 years ago
Interventions
AST-VAC2biological
Allogeneic dendritic cell vaccine.